Please use this identifier to cite or link to this item: http://hdl.handle.net/2445/179082
Title: Methylprednisolone Pulses Plus Tacrolimus in Addition to Standard of Care vs. Standard of Care Alone in Patients With Severe COVID-19. A Randomized Controlled Trial
Author: Solanich, Xavier
Antolí, Arnau
Rocamora Blanch, Gemma
Padullés Zamora, Núria
Fanlo Maresma, Marta
Iriarte, Adriana
Mitjavila, Francesca
Capdevila, Olga
Riera Mestre, Antoni
Bas, Jordi
Vicens Zygmunt, Vanesa
Niubó, Jordi
Calvo, Nahum
Bolivar, Santiago
Rigo Bonnin, Raúl
Mensa Vilaró, Anna
Arregui, Laura
Tebé, Cristian
Videla, Sebas
Hereu, Pilar
Corbella, Xavier
Keywords: COVID-19
Assaigs clínics
COVID-19
Clinical trials
Issue Date: 14-Jun-2021
Publisher: Frontiers Media SA
Abstract: Introduction: Severe lung injury is triggered by both the SARS-CoV-2 infection and the subsequent host-immune response in some COVID-19 patients. Methods: We conducted a randomized, single-center, open-label, phase II trial with the aim to evaluate the efficacy and safety of methylprednisolone pulses and tacrolimus plus standard of care (SoC) vs. SoC alone, in hospitalized patients with severe COVID-19. The primary outcome was time to clinical stability within 56 days after randomization. Results: From April 1 to May 2, 2020, 55 patients were prospectively included for subsequent randomization; 27 were assigned to the experimental group and 28 to the control group. The experimental treatment was not associated with a difference in time to clinical stability (hazard ratio 0.73 [95% CI 0.39-1.37]) nor most secondary outcomes. Median methylprednisolone cumulative doses were significantly lower (360 mg [IQR 360-842] vs. 870 mg [IQR 364-1451]; p = 0.007), and administered for a shorter time (median of 4.00 days [3.00-17.5] vs. 18.5 days [3.00-53.2]; p = 0.011) in the experimental group than in the control group. Although not statistically significant, those receiving the experimental therapy showed a numerically lower all-cause mortality than those receiving SoC, especially at day 10 [2 (7.41%) vs. 5 (17.9%); OR 0.39 (95% CI 0.05-2.1); p = 0.282]. The total number of non-serious adverse events was 42 in each the two groups. Those receiving experimental treatment had a numerically higher rate of non-serious infectious adverse events [16 (38%) vs. 10 (24%)] and serious infectious adverse events [7 (35%) vs. 3 (23%)] than those receiving SoC. Conclusions: The combined use of methylprednisolone pulses plus tacrolimus, in addition to the SoC, did not significantly improve the time to clinical stability or other secondary outcomes compared with the SoC alone in severe COVID-19. Although not statistically significant, patients receiving the experimental therapy had numerically lower all-cause mortality than those receiving SoC, supporting recent non-randomized studies with calcineurin inhibitors. It is noteworthy that the present trial had a limited sample size and several other limitations. Therefore, further RCTs should be done to assess the efficacy and safety of tacrolimus to tackle the inflammatory stages of COVID-19.
Note: Reproducció del document publicat a: https://doi.org/10.3389/fmed.2021.691712
It is part of: Frontiers in Medicine, 2021, vol. 8, num. 691712
URI: http://hdl.handle.net/2445/179082
Related resource: https://doi.org/10.3389/fmed.2021.691712
Appears in Collections:Articles publicats en revistes (Ciències Clíniques)
Articles publicats en revistes (Institut d'lnvestigació Biomèdica de Bellvitge (IDIBELL))
Articles publicats en revistes (Patologia i Terapèutica Experimental)

Files in This Item:
File Description SizeFormat 
fmed-08-691712.pdf816.36 kBAdobe PDFView/Open


This item is licensed under a Creative Commons License Creative Commons